- €5.67bn
- €18.16bn
- €6.59bn
- 59
- 64
- 16
- 41
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 9.45 | ||
| PEG Ratio (f) | 0.3 | ||
| EPS Growth (f) | 46.46% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.97 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.86 | ||
| EV to EBITDA | 15.42 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 4.18% | ||
| Return on Equity | 0.99% | ||
| Operating Margin | 12.13% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | 5,098.69 | 5,340.04 | 4,933.12 | 6,063.97 | 6,591.98 | 7,042.28 | 7,534.19 | 8% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +14.35 | +6.24 | +3.59 | -53.32 | +5.07 | +56.6 | +31.64 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. It organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Bio Supplies provides, mostly, biological products for non-therapeutic use. Others provides manufacturing services to third party companies.
Directors
- Victor Grifols Roura NEC
- Victor Grifols Deu CCE
- Raimon Grifols Roura CCE
- Thomas Glanzmann NVC (62)
- Alfredo Arroyo Guerra CFO
- Joel Abelson CEX
- Albert Coma-Cros CEX
- Alberto Grifols Roura CEX
- Chris Healey CEX
- Miguel Pascual Montblanch CEX
- Mateo Borras Humbert CHO
- Javier Sueiras Gil CTO
- Vicente Blanquer Torre VPR
- Matt Murawski VPR
- Nuria Pascual Lapena VPR
- Maria Rione VPR
- David Bell GCN (67)
- Luis Twose Garcon MDR
- Daniel Fleta Coit OTH
- Lafmin Morgan OTH (55)
- Nuria Martin Barnes SEC
- Tomas Daga Gelabert ASC
- Inigo Sanchez Asiain Mardones LED
- Ramon Riera Roca DRC
- James Costos IND (57)
- Marla Elizabeth Salmon IND
- Enriqueta Felip Font IND
- Steven Mayer IND (59)
- Carina Szpilka Lazaro IND (52)
- Belen Villalonga Morenes IND
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- June 22nd, 1987
- Public Since
- May 17th, 2006
- No. of Employees
- 23,744
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
Madrid Stock Exchange- Shares in Issue
- 679,092,279
- Address
- C/ Jesus y Maria, 6, BARCELONA, 08022
- Web
- https://www.grifols.com/
- Phone
- +34 935710000
- Auditors
- KPMG Auditores, SL
Latest News for GRF
Upcoming Events for GRF
Q1 2024 Grifols SA Earnings Release
Grifols SA Annual Shareholders Meeting
Similar to GRF
1nkemia IUCT SA
Madrid Stock Exchange
Almirall SA
Madrid Stock Exchange
Faes Farma SA
Madrid Stock Exchange
Labiana Health SA
Madrid Stock Exchange
Laboratorio Reig Jofre SA
Madrid Stock Exchange
FAQ
As of Today at 19:09 UTC, shares in Grifols SA are trading at €8.35. This share price information is delayed by 15 minutes.
Shares in Grifols SA last closed at €8.35 and the price had moved by -10.57% over the past 365 days. In terms of relative price strength the Grifols SA share price has underperformed the FTSE Global All Cap Index by -16.04% over the past year.
The overall consensus recommendation for Grifols SA is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Grifols SA does not currently pay a dividend.
Grifols SA does not currently pay a dividend.
Grifols SA does not currently pay a dividend.
To buy shares in Grifols SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of €8.35, shares in Grifols SA had a market capitalisation of €5.67bn.
Here are the trading details for Grifols SA:
- Country of listing: Spain
- Exchange: MCE
- Ticker Symbol: GRF
Based on an overall assessment of its quality, value and momentum Grifols SA is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Grifols SA is €17.70. That is 112.08% above the last closing price of €8.35.
Analysts covering Grifols SA currently have a consensus Earnings Per Share (EPS) forecast of €0.81 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Grifols SA. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -30.43%.
As of the last closing price of €8.35, shares in Grifols SA were trading -27.34% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Grifols SA PE ratio based on its reported earnings over the past 12 months is 9.45. The shares last closed at €8.35.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Grifols SA's management team is headed by:
- Victor Grifols Roura - NEC
- Victor Grifols Deu - CCE
- Raimon Grifols Roura - CCE
- Thomas Glanzmann - NVC
- Alfredo Arroyo Guerra - CFO
- Joel Abelson - CEX
- Albert Coma-Cros - CEX
- Alberto Grifols Roura - CEX
- Chris Healey - CEX
- Miguel Pascual Montblanch - CEX
- Mateo Borras Humbert - CHO
- Javier Sueiras Gil - CTO
- Vicente Blanquer Torre - VPR
- Matt Murawski - VPR
- Nuria Pascual Lapena - VPR
- Maria Rione - VPR
- David Bell - GCN
- Luis Twose Garcon - MDR
- Daniel Fleta Coit - OTH
- Lafmin Morgan - OTH
- Nuria Martin Barnes - SEC
- Tomas Daga Gelabert - ASC
- Inigo Sanchez Asiain Mardones - LED
- Ramon Riera Roca - DRC
- James Costos - IND
- Marla Elizabeth Salmon - IND
- Enriqueta Felip Font - IND
- Steven Mayer - IND
- Carina Szpilka Lazaro - IND
- Belen Villalonga Morenes - IND